Ribomic (TSE:4591) Cash Flow from Operations: 円-1,110.86 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4591 Ribomic Inc TSE:4591
26 GF Score
Price 円73.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Cash Flow from Operations?

Ribomic TSE:4591 26 Cash Flow from Operations is 円-1,110.86 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Mar. 2026, Ribomic's Net Income From Continuing Operations was 円-630.59 Mil. Its Depreciation, Depletion and Amortization was 円2.14 Mil. Its Change In Working Capital was 円37.02 Mil. Its cash flow from deferred tax was 円0.00 Mil. Its Cash from Discontinued Operating Activities was 円0.00 Mil. Its Asset Impairment Charge was 円0.00 Mil. Its Stock Based Compensation was 円0.00 Mil. And its Cash Flow from Others was 円-16.95 Mil. In all, Ribomic's Cash Flow from Operations for the six months ended in Mar. 2026 was 円-608.38 Mil.


Ribomic  (TSE:4591) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Ribomic's net income from continuing operations for the six months ended in Mar. 2026 was 円-630.59 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Ribomic's depreciation, depletion and amortization for the six months ended in Mar. 2026 was 円2.14 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Ribomic's change in working capital for the six months ended in Mar. 2026 was 円37.02 Mil. It means Ribomic's working capital increased by 円37.02 Mil from Sep. 2025 to Mar. 2026 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Ribomic's cash flow from deferred tax for the six months ended in Mar. 2026 was 円0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Ribomic's cash from discontinued operating Activities for the six months ended in Mar. 2026 was 円0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Ribomic's asset impairment charge for the six months ended in Mar. 2026 was 円0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Ribomic's stock based compensation for the six months ended in Mar. 2026 was 円0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Ribomic's cash flow from others for the six months ended in Mar. 2026 was 円-16.95 Mil.


Ribomic Cash Flow from Operations Related Terms


Ribomic Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Ribomic's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Cash Flow from Operations Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,499.22 -1,708.63 -932.76 -996.97 -1,110.86

Ribomic Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -385.20 -475.32 -521.65 -502.48 -608.38
TSE:4591
26GF Score
Ribomic Inc TSE:4591
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Ribomic's Cash Flow from Operations for the fiscal year that ended in Mar. 2026 is calculated as:

Ribomic's Cash Flow from Operations for the quarter that ended in Mar. 2026 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-1,110.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of 円-1,110.86 Mil mean?
Ribomic (TSE:4591) has a Cash Flow from Operations of 円-1,110.86 Mil as of Mar. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Ribomic and its competitors.
Is Ribomic's Cash Flow from Operations too high?
Ribomic's current Cash Flow from Operations is 円-1,110.86 Mil. Overall, Ribomic has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Cash Flow from Operations compare to VRTX and REGN?
Ribomic's Cash Flow from Operations of 円-1,110.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Ribomic and its competitors. Ribomic's current Cash Flow from Operations is 円-1,110.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Cash Flow from Operations of 円-1,110.86 Mil. The current Cash Flow from Operations is 円-1,110.86 Mil. Ribomic's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Cash Flow from Operations is 円-1,110.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
26GF Score

Get the complete analysis for TSE:4591

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円73.00
Price